In the high-stakes global competition to supply affordable weight-loss medications, Bangladesh has secured a significant early-mover advantage, leaving Indian pharmaceutical heavyweights playing catch-up. While recent court rulings have greenlit exports for Indian companies, Bangladeshi manufacturers have been flooding emerging markets with low-cost generic versions of the blockbuster drug semaglutide for over two years.
Indian Giants Get Legal Nod, But Face Established Rival
The Delhi High Court delivered separate judgements in early December 2025, permitting Dr Reddy’s Laboratories and Sun Pharmaceutical Industries to manufacture and export generic semaglutide to countries where patent exclusivity does not apply. Crucially, both firms are barred from selling the drug within India until the innovator Novo Nordisk loses its patent-protected monopoly in March 2026.
This legal move is widely seen as a strategic play to establish an early presence in international markets. However, the path is not uncharted. Bangladesh, leveraging its ‘Least-Developed Country’ (LDC) status under World Trade Organization rules, has been exempt from granting full pharmaceutical patents. This exemption, valid until 2030, allows its companies to legally reverse-engineer and produce patented drugs, a advantage India itself enjoyed until 2005.
Bangladesh's Formidable Head Start and Expanding Portfolio
Capitalizing on this regulatory framework, Bangladesh's pharmaceutical sector has been a prolific exporter of generic semaglutide since 2022. At least seven local companies manufacture the drug, with four major players—Beximco, Ziska Pharmaceuticals, ACI Ltd, and Incepta Pharmaceuticals—leading exports to Latin America, APAC, and Africa.
Ravindra Singha, MD of Firmlink Pharma, notes that Bangladesh currently holds the largest share of semaglutide exports to non-patented regions, as their products are "already tried and tested." The country has also synthesized tirzepatide, the compound in Eli Lilly's Mounjaro, and has been producing it for seven months, with exports to countries like Pakistan already facing supply shortages.
Namit Joshi, Chairman of Pharmexcil, highlights Bangladesh's cost edge: "Bangladesh imports cheap raw materials and peptides from China, and has a lower labour cost, hence the fixed cost is much lower than India."
The Road Ahead for Indian Pharma: Brand Trust vs. Price War
While the competition in less-regulated 'rest-of-the-world' markets will be intense, analysts point to India's inherent strengths. Vishal Manchanda of Systematix Group suggests that emerging market sales for semaglutide may not be sizable for Indian companies initially, with larger opportunities in markets like Brazil and Canada.
However, in regulated markets, brand trust and quality compliance often trump low prices. Here, India's formidable reputation as a reliable supplier with numerous US FDA-approved manufacturing sites provides a critical edge. Joshi emphasized India's position as the largest holder of such sites outside the US, offering significant scale and formulation advantages.
Furthermore, India's political stability and established role as the 'pharmacy of the world'—with pharmaceutical exports reaching $30.47 billion in FY25—contrast with Bangladesh's recent political crises, offering long-term supply chain reliability that global markets value.
The race for the global weight-loss drug market is just heating up. While Bangladesh enjoys a cost and timing advantage today, the coming years will test the mettle of Indian pharma's regulatory prowess, brand-building capabilities, and its ability to leverage domestic scale when the patent gates open fully in 2026.
